JMP Securities analyst Konstantinos Aprilakis lowered his price target on Idera Pharmaceuticals to $4 from $8 after the company's Phase 2 trial of IMO-8400 in the dermatomyositis setting did not meet its primary endpoint. While he views this latest development for IMO-8400 as disappointing, he reminds investors of the positive tilsotolimod data recently presented at ASCO and still thinks tilsotolimod plus ipilimumab has the potential for a favorable competitive profile in the anti PD-1 refractory melanoma setting. Aprilakis keeps an Outperform rating on Idera shares.